DouglasYeeMD
Oncology • Minneapolis, MNBreast Cancer, Hematologic Oncology
Professor of Medicine Director, Masonic Cancer Center, University of Minnesota
Dr. Yee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Masonic Cancer Center, University of Minnesota
420 Delaware Street SE
Minneapolis, MN 55455Phone+1 612-626-8487
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
University of North Carolina HospitalsResidency, Internal Medicine, 1981 - 1985
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1981
Certifications & Licensure
MN State Medical License 1999 - 2025
TX State Medical License 1989 - 2007
NC State Medical License 1984 - 1999- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer Start of enrollment: 2006 Jul 01
- CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery
- Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca Start of enrollment: 2008 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.Hope S Rugo, Mike Campbell, Christina Yau, A Jo Chien, Anne M Wallace
Breast Cancer Research and Treatment. 2024-12-03 - A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.Katherine Leggat-Barr, Douglas Yee, Erin Duralde, Caroline Hodge, Virginia Borges
Breast Cancer Research and Treatment. 2024-11-12 - Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.Mark Jesus M Magbanua, Ziad Ahmed, Rosalyn W Sayaman, Lamorna Brown Swigart, Gillian L Hirst
Clinical Cancer Research. 2024-06-03
Lectures
- The DNA Cytosine Deaminase APOBEC3B Promotes Tamoxifen Resistance in ER-Positive Breast CancerAmerican Society of Clinical Oncology(ASCO), Chicago, Illinois - 8/9/2013
- The DNA Cytosine Deaminase APOBEC3B Promotes Tamoxifen Resistance in ER-Positive Breast CancerAmerican Society of Clinical Oncology(ASCO), Los Angeles, California - 8/16/2013
Press Mentions
Meet the Group Making Cancer Trials More Equitable in MinnesotaNovember 13th, 2024- What Black Women Should Know on Metastatic Breast Cancer Awareness DayOctober 16th, 2024
- What Black Women Should Know About Metastatic Breast CancerOctober 14th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
